

New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

New Drug Product Medication Request

DATE OF MEDICATION REQUEST: /

SECTION I: PATIENT INFORMATION AND MEDICATION	`													
LAST NAME:	FIRST NAME:													
MEDICAID ID NUMBER:	DATE OF BIRTH:													
GENDER: Male Female														
Drug Name:	Strength:													
Dosing Directions:	Length of Therapy:													
SECTION II: PRESCRIBER INFORMATION														
LAST NAME:	FIRST NAME:													
SPECIALTY:	NPI NUMBER:													
PHONE NUMBER:	FAX NUMBER:													
SECTION III: CLINICAL HISTORY														
What is the rationale for this request for restricted n	nedication?													
Allergic reaction Drug-to-drug interaction	on													
Please describe the reaction:														
Please provide information about any previous episor	des of an unacceptable side effect or therapeutic failure.													
Please provide clinical information:	·													
•														

(Form continued on next page.)

© 2021–2024 by Magellan Rx Management, LLC. All rights reserved. **Phone**: 1-866-675-7755 **Fax**: 1-888-603-7696

Review Date: 01/29/2024





New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

New Drug Product Medication Request

DATE OF MEDICATION REQUEST:	/	/
-----------------------------	---	---

PATIENT LAST NAME:													PATIENT FIRST NAME:												
SE	CTION	III: CI	INICA	L HIST	ΓORY	(Con	ntinu	ed)																	
	Please contra	lease provide information about any clinical contraindication, co-morbidity, or unique patient circumstance as a ontraindication to a preferred drug. lease provide clinical information:															e as a								
4.		Please provide information about any age-specific indications. Please provide patient age and explain:																							
5.	Please provide information about any unique clinical indication supported by FDA approval or peer-reviewed literature. Please explain and provide a reference:														b b										
6.		Please provide information about any unacceptable clinical risk associated with therapeutic change. Please explain:																							
7.	Is ther	•						at w	ould	help	in th	ne de	ecisio	on-m	nakin	g pro	cess	? If ac	dditio	nal s	pace	is			
	rtify th				-							-					-		_			rstand	d that		
PRE	SCRIBI	ER'S S	IGNAT	URE:													_DA	ΓE:							

Phone: 1-866-675-7755 **Fax**: 1-888-603-7696

